Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Lorus Therapeutics Inc. -- Ignore unavailable to you. Want to Upgrade?

To: trustmanic who wrote (209)	11/12/1998 9:27:00 AM
From: DaveAu	Read Replies (1) \| Respond to of 279

NOVEMBER 12, 1998 Imutec Pharma Releases Additional Pancreatic Cancer Data TORONTO, ONTARIO-- --- Results of recent studies to support filings for pivotal trials --- Imutec Pharma Inc. today announced additional preclinical data on the efficacy of its lead anti-cancer product, Virulizin(R). These data were obtained from studies performed at the University of Nebraska Medical Center. Imutec Pharma performed these supporting studies, to determine the efficacy of Virulizin(R) in combination with Gemzar(R), in a human tumor xenograft model commonly used for pancreatic cancer. After extended daily administration, Virulizin(R) inhibited tumor growth in this model to approximately the same extent as Gemzar(R), the standard for first-line treatment of pancreatic cancer. Furthermore, Virulizin(R) showed a statistically significant additive anti-tumour activity when combined with Gemzar(R). In addition, no adverse effects related to the administration of Virulizin(R) were observed. "We are encouraged by these results", commented Philippe G. Lacaille, President and Chief Executive Officer of Imutec Pharma. "These positive data from a human tumor xenograft model are consistent with the very positive clinical trial results we recently achieved. These date will add support to our regulatory filings for a pivotal clinical trial program in North America for pancreatic cancer." In August 1998, Imutec Pharma announced positive results regarding its Virulizin(R) Phase I/II pancreatic cancer trial at the Rush Presbyterian St. Luke's Medical Center in Chicago. The overall median survival of 6.8 months, and the six-month survival rate of 58 percent, confirm and extend previous studies performed by the Company in Canada in pancreatic cancer patients. In the main Phase II trial of Gemzar(R) in patients with 5-FU refractory pancreatic cancer, the median survival was 3.85 months with a 6-month survival of 31 percent. The results of the recent Imutec Pharma trial document that Virulizin(R) has clinical activity that is at least as good as what has been reported for Gemzar(R), in previously treated patients, with a much better safety profile. Imutec Pharma Inc. is a pharmaceutical company engaged in the development and commercialization of innovative products for the treatment of cancer. Through an active acquisition and in-licensing program, Imutec Pharma's goal is to build and clinically develop a portfolio of innovative drugs targeted at life-threatening diseases. Thereafter, Imutec Pharma intends to undertake late stage clinical development and marketing in cooperation with strategic pharmaceutical partners. Founded in 1986, Imutec Pharma Inc. is a public company listed on the Toronto Stock Exchange and the Montreal Stock Exchange under the symbol IMT, and on the NASDAQ OTC Bulletin Board under the symbol IMUTF. Except for historical information, this press release contains forward-looking statements which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties which may cause actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual reports and 20-F filings. Imutec Pharma's press releases are available through the Company's Internet site: imutec.com -30- FOR FURTHER INFORMATION PLEASE CONTACT: Imutec Pharma Inc. Paul W. Truscott, Jr. Associate, Corporate Communications (416) 724-1509, ext. 251 (416) 724-1167 (FAX) Email: imutec@inforamp.net